IMPACTT Project

The IMPACTT Project started on January 1st 2011 and is a collaboration between ten partners from seven European countries (Sweden, Germany, Denmark, Belgium, France, Italy, and Lithuania). IMPACTT is supported by the European Union Seventh Framework Programme with 5,4 million Euro during 4 years.

The IMPACTT project will complete a clinical phase III trial, to demonstrate the critical preventive and therapeutic effects of a pioneering intervention therapy (based on the avian polyclonal Anti-Pseudomonas IgY formulation) for the fatal chronic infection of Pseudomonas aeruginosa in CF patients. The project mobilizes the critical mass of experts from academia, patient organizations, clinical trials managers, clinicians and industry aiming to prevent PA infections in CF patient lungs and thereby alleviate their negative impact on the quality of life of CF patients and their families; To this, a parallel objective is to explore ways of meaningfully involving patients and family members into clinical CF research.